A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint

被引:0
|
作者
Qing, Yun [1 ,2 ]
Thall, Peter F. [1 ]
Yuan, Ying [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX 77030 USA
关键词
Bayesian adaptive design; futility monitoring; go; no-go decision; interim analysis; OPTIMAL 2-STAGE DESIGNS; CLINICAL-TRIALS; SURVIVAL; SAMPLE;
D O I
10.1002/pst.2256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A robust Bayesian design is presented for a single-arm phase II trial with an early stopping rule to monitor a time to event endpoint. The assumed model is a piecewise exponential distribution with non-informative gamma priors on the hazard parameters in subintervals of a fixed follow up interval. As an additional comparator, we also define and evaluate a version of the design based on an assumed Weibull distribution. Except for the assumed models, the piecewise exponential and Weibull model based designs are identical to an established design that assumes an exponential event time distribution with an inverse gamma prior on the mean event time. The three designs are compared by simulation under several log-logistic and Weibull distributions having different shape parameters, and for different monitoring schedules. The simulations show that, compared to the exponential inverse gamma model based design, the piecewise exponential design has substantially better performance, with much higher probabilities of correctly stopping the trial early, and shorter and less variable trial duration, when the assumed median event time is unacceptably low. Compared to the Weibull model based design, the piecewise exponential design does a much better job of maintaining small incorrect stopping probabilities in cases where the true median survival time is desirably large.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 50 条
  • [21] Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
    Xiudong Lei
    Ying Yuan
    Guosheng Yin
    Lifetime Data Analysis, 2011, 17 : 156 - 174
  • [22] Time-to-event Bayesian optimal interval design to accelerate phase I pediatric oncology trials
    Yuan, Ying
    Lin, Ruitao
    Li, Daniel
    Nie, Lei
    Warren, Katherine
    CANCER RESEARCH, 2020, 80 (14) : 52 - 52
  • [23] Analysis of a composite endpoint with longitudinal and time-to-event data
    Tseng, Chi-hong
    Wong, Weng Kee
    STATISTICS IN MEDICINE, 2011, 30 (09) : 1018 - 1027
  • [24] Consideration of stratification in confirmatory trials with time-to-event endpoint
    Wang, Yizhuo
    Zhou, Xuan
    Guo, Zifang
    Fang, Xiao
    Liu, Fang
    Shen, Liji
    CONTEMPORARY CLINICAL TRIALS, 2024, 141
  • [25] The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints
    Huang, Xinran
    Wang, Jian
    Ning, Jing
    STATISTICS IN MEDICINE, 2024, 43 (30) : 5922 - 5934
  • [26] A randomized Bayesian optimal phase II design with binary endpoint
    Ding, Yang
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (02) : 151 - 166
  • [27] OPTIMAL FUTILITY INTERIM DESIGN: A PREDICTIVE PROBABILITY OF SUCCESS APPROACH WITH TIME-TO-EVENT ENDPOINT
    Tang, Zhongwen
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (06) : 1312 - 1319
  • [28] Designing phase II studies in cancer with time-to-event endpoints
    Owzar, Kouros
    Jung, Sin-Ho
    CLINICAL TRIALS, 2008, 5 (03) : 209 - 221
  • [29] Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints
    Shi, Haolun
    Yin, Guosheng
    BIOMETRICS, 2018, 74 (03) : 1055 - 1064
  • [30] Approximation of Bayesian models for time-to-event data
    Catalano, Marta
    Lijoi, Antonio
    Prunster, Igor
    ELECTRONIC JOURNAL OF STATISTICS, 2020, 14 (02): : 3366 - 3395